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Maximum beneﬁ t of chemotherapy for osteosarcoma 
achieved—what are the next steps?
unknown primary is hampered by the inability of direct 
validation, because, by deﬁ nition, the primary cancer 
diagnosis cannot be veriﬁ ed. In the study by Moran and 
colleagues, the results of the EPICUP assay were validated 
based on pathological features and observation of latent 
primaries. Ideally, validation of tumour of origin should 
be based on patients’ autopsies in a prospective study; 
however, in view of legal and ethical issues, such studies 
are very diﬃ  cult to do in current clinical practice. 
Historically, cancer of unknown primary has been 
viewed as a distinct disease entity, mainly treated 
with empirical chemotherapy, and most patients 
have a dismal prognosis, with a median survival of 
9 months.7 Moran and colleagues noted that patients 
who were treated with site-speciﬁ c therapy based on 
their EPICUP diagnosis had improved overall survival 
(hazard ratio 3·24, 95% CI 1·42–7·38; p=0·0051). 
Consistent with this result, in a large prospective study, 
patients who received site-speciﬁ c therapy based 
on tumour of origin molecular assays, had a median 
survival of 12·5 months compared with historical 
controls,8 although this study has received major 
criticism because of design limitations, namely lack 
of randomisation.9 In the current era of personalised 
medicine, there is a push towards individualising 
patient management; however, due to the rarity of 
cancer of unknown primary, no randomised study 
has ever been done for patients receiving site-speciﬁ c 
therapy compared with empirical therapy. Ideally, a 
well-designed prospective randomised study could 
help to identify subsets of patients who would 
beneﬁ t more from targeted therapies, with the view 
to improve clinical outcomes without maximising 
costs. Two randomised studies assessing the eﬃ  cacy 
of molecular proﬁ ling-based treatment in metastatic 
cancers are currently recruiting patients (NCT01827384 
and NCT02152254). However, a question that remains 
unanswered is whether a cancer of unknown primary 
with a molecular signature of a speciﬁ c primary behaves 
similarly to a typical metastatic cancer. 
In conclusion, it is becoming increasingly clear that 
further research in the ﬁ eld of molecular biology is the 
key to our understanding of cancer of unknown primary 
biology. A vision of the future would be the creation of 
a clinically useful diagnostic algorithm, which would 
incorporate pathological ﬁ ndings and molecular 
proﬁ ling tests along with crucial clinical judgment to 
maximise clinical beneﬁ t and limit costs. 
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The survival rates for osteosarcoma have remained 
stagnant at 60–65% for more than 25 years. The 
three-drug chemotherapy regimen of cisplatin, 
doxorubicin, and methotrexate (MAP) form the 
backbone therapy, and response to induction 
chemotherapy correlates with patient outcome.1 
Debate remains about the usefulness of adding 
dose-intensive ifosphamide with or without etoposide 
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to the three-drug MAP regimen (MAPIE) to improve 
the outcome of patients with a poor response (deﬁ ned 
as ≤90% tum our necrosis) to induction chemotherapy. 
The results of the EURAMOS-1 international trial 
presented in The Lancet Oncology,2 focused on patients 
with newly diagnosed, non-metastatic osteosarcoma, 
who had a poor response (≤90% tumour necrosis) 
after neoadjuvant three-drug chemotherapy (MAP) 
and were randomly assigned postoperatively to MAP 
or MAP plus high dose ifosphamide (dose used was 
14 g/m² at 2·8 g/m² per day) and etoposide (MAPIE). 
The study aimed to establish whether the addition of 
ifosphamide and etoposide, previously thought to 
improve outcome, would have a signiﬁ cant eﬀ ect on 
event-free (the primary endpoint) and overall survival. 
No diﬀ erence in either event-free survival (hazard ratio 
[HR] 0·98 [95% CI 0·78–1·23]) or overall survival was 
seen between the two groups.
The EURAMOS-1 study shows that international 
collaborations are feasible, can be used to increase 
accrual of patient numbers, and are a powerful 
approach to studying rare cancers. This is the ﬁ rst 
randomised trial to investigate this important 
question, and not only shows that there was no patient 
beneﬁ t from ifosphamide and etoposide but also that 
there was an signiﬁ cant increase in regimen toxicity 
for high-grade non-haematological adverse events 
(p=0·0024), particularly in grade 4 non-haematological 
adverse events (35 [12%] of 301 in the MAP group vs 
71 [24%] of 298 in the MAPIE group). This study is 
both timely and important because it provides crucial 
information for oncologists on how to approach the 
care of paediatric, adolescent, and young adult patients 
with osteosarcoma who have responded poorly to 
preoperative chemotherapy.
Two other randomised trials3,4 investigated whether 
the addition of ifosphamide at the standard dose 
improved the 60–65% survival of patients with 
osteosarcoma achieved with the three-drug regimen. 
Similar to the EURAMOS-1 trial, the Children’s Oncology 
Group (COG) trial reported in 2008,3 and the Italian 
Sarcoma Group trial reported in 2012,4 showed no 
beneﬁ t in adding ifosphamide to the three drug 
regimen as judged by event-free survival and overall 
survival. A meta-analysis published in 2011 showed 
that although treatment with three drugs is superior 
to that with two drugs, no beneﬁ t existed for using 
four drugs compared with three drugs.5 Therefore, 
despite increasing the dose of ifosphamide and 
adding etoposide to the postoperative treatment, the 
EURAMOS-1 study corroborated the previous ﬁ ndings. 
The authors suggested that because ifosphamide and 
etoposide therapy was not initiated until week ﬁ ve 
postoperatively, this delay might account for the lack 
of beneﬁ t of the more intensive regimen. However, 
this theory is questionable in light of these two trials, 
which initiated therapy with ifosphamide earlier than 
the EURAMOS-1 study.3,4 Although the study design for 
the COG trial was diﬀ erent to that of the EURAMOS-1 
trial in that ifosphamide was substituted for cisplatin 
in the preoperative regimen, the number of courses of 
cisplatin, doxorubicin, and methotrexate administered 
to patients was the same in both groups. The only 
diﬀ erence was the addition of ifosphamide, and in this 
trial, ifosphamide was administered early in the course 
of treatment.3 In addition to showing no improvement 
in event-free survival and overall survival, the COG 
trial also showed that there was no beneﬁ t in use of 
ifosphamide preoperatively because the percentage 
of patients with a good response to induction therapy 
was the same with or without ifosphamide. Because 
response to induction chemotherapy is the only reliable 
marker of patient outcome,1 these ﬁ ndings support the 
conclusion that ifosphamide at either the standard-dose 
or high-dose provides no patient beneﬁ t.  
The time has come to put aside the hope that the 
addition of ifosphamide (standard-dose or high-dose, 
with or without etoposide) will provide the long 
sought answer to improving the 65–70% overall 
survival achieved with the three-drug regimen, 
cisplatin, doxorubicin, and methotrexate. Ifosphamide 
was introduced more than 30 years ago and tested 
in multiple randomised and non-randomised trials. 
Although responses to ifosphamide have been 
observed, this has not been translated into longer 
survival, the most important variable.6 The toxicity 
of adding ifosphamide with or without etopiside has 
also been documented many times, most recently 
in the EURAMOS-1 study. The addition of high-dose 
ifosphamide plus etoposide resulted in increased 
toxicity and more cases of secondary leukaemia, 
which is by stark contrast with the addition of the 
immunotherapy mifamuride to the three-drug 
regimen, which resulted in a reduction in mortality 
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The heterogeneity of the disease course and outcome 
in patients with chronic lymphocytic leukaemia 
is well known in haematological oncology.1 This 
heterogeneity is exempliﬁ ed by patients who carry 
aberrations in the TP53 gene, namely deletion 17p 
(del17p) or mutations in this gene. These patients 
generally have an aggressive disease and diminished 
life expectancy, mainly because of a paucity of 
treatment options owing to the ineﬃ  cacy of 
chemoimmunotherapy-based regimens. Allogeneic 
transplantation may be the only viable treatment 
option for these patients, although this is often not 
possible because this disease is more common in older 
patients who are unable to undergo such procedure.1
Recently, the poor prognosis for these patients has 
improved radically with the approval of new kinase 
inhibitors (often deﬁ ned as BCR inhibitors) that seem 
to be equally active in this high-risk group of patients. 
This impression mainly originated from ﬁ ndings from 
subgroup analyses of phase 1b/2 and 3 trials that 
showed, for example in the case of the BTK inhibitor 
ibrutinib,2–4 that patients with chronic lymphocytic 
leukaemia carrying del17p responded as well as 
those without this deletion, and achieved a longer 
progression-free survival than that with other 
treatments in the relapsed or refractory setting and 
more than double that achieved by the ﬂ udarabine, 
cyclophosphamide, and rituximab combination in 
treatment-naive patients.
For these reasons and despite the absence of robust 
scientiﬁ c evidence, ibrutinib (and similarly the PI3Kδ 
inhibitor idelalisib in combination with rituximab 
that showed similar results to ibrutinib5) has also 
been approved by the regulatory agencies, with 
unprecedented foresight, for use in treatment-naive 
high-risk patients and adopted quickly by the 
haematological community as the treatment of 
choice for patients with TP53 aberrations in general.6,7 
The widespread recommendation on the use of 
ibrutinib in high-risk patients despite the absence 
of robust evidence could be described as a leap of 
faith; thus, Susan O’Brien and colleagues’ study8 
in The Lancet Oncology of the eﬃ  cacy of ibrutinib 
in 144 patients with relapsed or refractory chronic 
lymphocytic leukaemia carrying del17p (RESONATE-17) 
is reassuring. At the prespeciﬁ ed primary analysis 
(median follow-up of 11·5 months [IQR 11·1–13·8]), 
92 (64%, 95% CI 56–71) of 144 patients had 
reached the primary endpoint of an overall response 
as assessed by central review; in an extended 
analysis with a median follow-up of 27·6 months 
(IQR 14·6–27·7), 120 patients (83%, 95% CI 76–89) 
had an investigator-assessed overall response. Safety 
outcomes were similar to those reported previously. 
Others have shown that the quality of response with 
ibrutinib seems to improve over time9 and the same 
seemed to be true also among high-risk patients 
because the proportion of patients with a complete 
Ibrutinib holds promise for patients with 17p deletion CLL
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(HR 0·71 [95% CI 0·52–0·96]) and an increase in 
survival from 70% to 78% at 8 years.3 The success of 
mifamurtide shows that osteosarcoma is sensitive to 
immunotherapy, suggesting that this should be the 
focus for future international trials.
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